Search the Newsreel

Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain

Medtronic has completed its acquisition of SPR Therapeutics, Inc. for $650 million, integrating SPR's SPRINT® PNS System into its pain therapy portfolio. This expands Medtronic's offerings for chronic and acute pain management with a minimally invasive, non-opioid treatment that does not require a permanent …

Medtronic Adds 60-Day Pain Therapy Without Permanent Implant

Medtronic (NYSE: MDT) has completed its $650 million cash acquisition of SPR Therapeutics, adding the SPRINT® peripheral nerve stimulation (PNS) technology to its pain therapy portfolio. This acquisition expands Medtronic's offerings for minimally invasive, non-opioid treatments for chronic and acute pain, with clinical data …

Medtronic faces first trial in US hernia mesh injury cases

Medtronic's Covidien unit is facing its first jury trial in Boston over claims that its hernia-repair mesh implants caused injuries. The plaintiff, Larry Patterson, alleges a Symbotex mesh implant led to a bowel obstruction, while Medtronic argues the product worked as designed and other …

Medtronic stock holds steady as Q4 FY26 revenue exceeds consensus

Earnings Call Transkript: Medtronic übertrifft im vierten Quartal 2026 die Erwartungen bei Umsatz und Gewinn

Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT): Three Dividend Healthcare Stocks to Consider in 2026

Medtronic plc (MDT) Stock: Slips as MiniMed Targets $7.86B IPO Valuation

Medtronic plc: Finanzdaten Prognosen Schätzungen und Erwartungen | A14M2J | IE00BTN1Y115

Medtronic plc: Konsensus der Analysten und Kursziel | A14M2J | IE00BTN1Y115